BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 2017;130:537-41. [DOI: 10.1182/blood-2017-04-778175] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Jaeger U. Hot therapy for cold agglutinin disease. Blood 2017;130:392-3. [DOI: 10.1182/blood-2017-06-788463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol 2020;11:946. [PMID: 32655543 DOI: 10.3389/fimmu.2020.00946] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
3 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 277] [Article Influence: 104.7] [Reference Citation Analysis]
4 Gertz MA. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.11.001] [Reference Citation Analysis]
5 De Back TR, Kater AP, Tonino SH. Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. Expert Review of Hematology 2018;11:613-24. [DOI: 10.1080/17474086.2018.1489720] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
6 Fattizzo B, Barcellini W. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects. Front Oncol 2019;9:1435. [PMID: 31998632 DOI: 10.3389/fonc.2019.01435] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
7 Michel M, Jäger U. Autoimmune Hemolytic Anemia. Hematology. Elsevier; 2018. pp. 648-662.e1. [DOI: 10.1016/b978-0-323-35762-3.00046-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Röth A, Bommer M, Hüttmann A, Herich-Terhürne D, Kuklik N, Rekowski J, Lenz V, Schrezenmeier H, Dührsen U. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv 2018;2:2543-9. [PMID: 30291112 DOI: 10.1182/bloodadvances.2018024190] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
9 Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev 2021;3:CD012493. [PMID: 33786812 DOI: 10.1002/14651858.CD012493.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Herbreteau L, Le Calloch R, Arnaud B, Cassou N, Rizcallah MJ, Hutin P, Le Clech L. Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders. Ann Hematol 2021;100:2105-6. [PMID: 34003325 DOI: 10.1007/s00277-021-04557-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Röth A. Do temperature and time matter in cold agglutinin disease? Blood 2020;136:380-1. [DOI: 10.1182/blood.2020006566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
13 Berentsen S. How I treat cold agglutinin disease. Blood 2021;137:1295-303. [PMID: 33512410 DOI: 10.1182/blood.2019003809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
14 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020;41:100648. [PMID: 31839434 DOI: 10.1016/j.blre.2019.100648] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis]
16 Sefland Ø, Randen U, Berentsen S. Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? Case Rep Hematol 2019;2019:1610632. [PMID: 30949369 DOI: 10.1155/2019/1610632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Wongsaengsak S, Czader M, Suvannasankha A. Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma. BMJ Case Rep 2018;2018:bcr-2017-222064. [PMID: 29991541 DOI: 10.1136/bcr-2017-222064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Jia MN, Qiu Y, Wu YY, Cai H, Zhou DB, Cao XX, Li J. Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients. Sci Rep 2020;10:12694. [PMID: 32728060 DOI: 10.1038/s41598-020-69465-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and perspectives. Immun Ageing 2020;17:38. [PMID: 33292368 DOI: 10.1186/s12979-020-00208-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020;136:480-8. [PMID: 32374875 DOI: 10.1182/blood.2020005674] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
21 Berentsen S. Cold agglutinins: fending off the attack. Blood 2019;133:885-6. [PMID: 30819775 DOI: 10.1182/blood-2019-01-894303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol 2020;11:590. [PMID: 32318071 DOI: 10.3389/fimmu.2020.00590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
23 Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol 2018;14:857-72. [PMID: 30204521 DOI: 10.1080/1744666X.2018.1521722] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
24 Lorenzo-Villalba N, Andres E, Guerrero-Niño J, Nasco E, Cattelan J, Jannot X, Ledoux MP. Frostbite and Cold Agglutinin Disease: Coexistence of Two Entities Leading to Poor Clinical Outcomes. Medicina (Kaunas) 2021;57:592. [PMID: 34201186 DOI: 10.3390/medicina57060592] [Reference Citation Analysis]
25 Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D’adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018;132:547-50. [DOI: 10.1182/blood-2018-03-835413] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
26 Li W, Yi J, Zheng X, Liu S, Fu W, Ren L, Li L, Hoon DSB, Wang J, Du G. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin Epigenetics 2018;10:64. [PMID: 29796115 DOI: 10.1186/s13148-018-0495-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
27 Röth A, Fryzek J, Jiang X, Reichert H, Patel P, Su J, Morales Arias J, Broome CM. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 2021. [PMID: 34813663 DOI: 10.1111/trf.16745] [Reference Citation Analysis]
28 Kamesaki T, Nishimura J, Wada H, Yu E, Tsao E, Morales J, Kanakura Y. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol 2020;112:307-15. [DOI: 10.1007/s12185-020-02899-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med 2019;10:93-103. [PMID: 31114413 DOI: 10.2147/JBM.S177621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
30 Berentsen S. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease. Semin Hematol 2018;55:141-9. [PMID: 30032751 DOI: 10.1053/j.seminhematol.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
31 Patriquin CJ, Pavenski K. O, wind, if winter comes … will symptoms be far behind?: Exploring the seasonality (or lack thereof) and management of cold agglutinin disease. Transfusion 2021. [PMID: 34893982 DOI: 10.1111/trf.16765] [Reference Citation Analysis]
32 Vitale C, Montalbano MC, Salvetti C, Boccellato E, Griggio V, Boccadoro M, Coscia M. Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. Cancers (Basel) 2020;12:E282. [PMID: 31979293 DOI: 10.3390/cancers12020282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
33 Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol 2018;181:320-30. [DOI: 10.1111/bjh.15109] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
34 Girard LP, Soekojo CY, Ooi M, Chng WJ, de Mel S. Immunoglobulin M Monoclonal Gammopathies of Clinical Significance. Front Oncol 2022;12:905484. [PMID: 35756635 DOI: 10.3389/fonc.2022.905484] [Reference Citation Analysis]
35 Małecka A, Trøen G, Delabie J, Małecki J, Østlie I, Tierens A, Randen U, Berentsen S, Tjønnfjord GE. The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels. Am J Hematol 2021;96:E279-83. [PMID: 33891703 DOI: 10.1002/ajh.26205] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood 2019;134:2022-35. [PMID: 31527073 DOI: 10.1182/blood.2019000725] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
37 Pratt G, El‐sharkawi D, Kothari J, D’sa S, Auer R, Mccarthy H, Krishna R, Miles O, Kyriakou C, Owen R. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. [DOI: 10.1111/bjh.18036] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 2019;10:2040620719873321. [PMID: 31523413 DOI: 10.1177/2040620719873321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
39 Autore F, Pasquale R, Innocenti I, Fresa A, Sora' F, Laurenti L. Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review. Cancers (Basel) 2021;13:5804. [PMID: 34830959 DOI: 10.3390/cancers13225804] [Reference Citation Analysis]
40 Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, Schenk TM, D'Sa S, Cartwright R, Gilbert JC, Jilma B, Jaeger U. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv 2020;4:997-1005. [PMID: 32176765 DOI: 10.1182/bloodadvances.2019001321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
41 Małecka A, Delabie J, Østlie I, Tierens A, Randen U, Berentsen S, Tjønnfjord GE, Trøen G. Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Adv 2020;4:993-6. [PMID: 32168377 DOI: 10.1182/bloodadvances.2020001608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Ribes D, Hachem HEL, Oberic L, Vergez F, Delas A, Belliere J, Protin C, Kamar N, Ferrandiz I, Tavitian S, Laurent C, Huart A, Chauveau D, Ysebaert L, Faguer S. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. Am J Hematol 2018;93:356-62. [PMID: 29168251 DOI: 10.1002/ajh.24984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Chao SH, Chang YL, Yen JC, Liao HT, Wu TH, Yu CL, Tsai CY, Chou YC. Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. Exp Hematol Oncol 2020;9:6. [PMID: 32322437 DOI: 10.1186/s40164-020-00163-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol 2022;:1-15. [PMID: 35702053 DOI: 10.1080/1744666X.2022.2089115] [Reference Citation Analysis]
46 Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2018;2018:382-9. [PMID: 30504336 DOI: 10.1182/asheducation-2018.1.382] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
47 Hwang SR, Saliba AN, Wolanskyj-Spinner AP. Immunotherapy-associated Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am 2022;36:365-80. [PMID: 35339260 DOI: 10.1016/j.hoc.2021.11.002] [Reference Citation Analysis]
48 Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 2019;133:893-901. [PMID: 30559259 DOI: 10.1182/blood-2018-06-856930] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
49 Schär DT, Daskalakis M, Mansouri B, Rovo A, Zeerleder S. Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study. Eur J Haematol 2022;108:45-51. [PMID: 34551149 DOI: 10.1111/ejh.13710] [Reference Citation Analysis]
50 Makishima K, Obara N, Ishitsuka K, Sukegawa S, Suma S, Kiyoki Y, Baba N, Sakamoto T, Kato T, Kusakabe M, Nishikii H, Kurita N, Yokoyama Y, Sakata-Yanagimoto M, Hasegawa Y, Chiba S. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Ann Hematol 2019;98:1031-2. [PMID: 30324459 DOI: 10.1007/s00277-018-3521-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
51 Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J Clin Med 2020;9:E3859. [PMID: 33261023 DOI: 10.3390/jcm9123859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
52 Tvedt THA, Steien E, Øvrebø B, Haaverstad R, Hobbs W, Wardęcki M, Tjønnfjord GE, Berentsen SA. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol 2022;97:E51-4. [PMID: 34778998 DOI: 10.1002/ajh.26409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W. Infectious Complications in Autoimmune Hemolytic Anemia. J Clin Med 2021;10:E164. [PMID: 33466516 DOI: 10.3390/jcm10010164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]